Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares of Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS) Director Rachel Humphrey sold 13,896 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $1.03, for a total value of $14,312.88. Following the completion of the transaction, the director owned 81,309 shares of the company’s stock, valued at $83,748.27. This trade represents a 14.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Pyxis Oncology Stock Up 5.1%

PYXS stock opened at $1.43 on Thursday. The stock has a market capitalization of $89.85 million, a price-to-earnings ratio of -1.11 and a beta of 1.45. Pyxis Oncology, Inc. has a 52-week low of $0.83 and a 52-week high of $5.55. The stock’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $2.50.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter. As a group, analysts anticipate that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after buying an additional 9,062 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Pyxis Oncology by 37.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock worth $58,000 after acquiring an additional 13,550 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Pyxis Oncology by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after acquiring an additional 14,566 shares during the last quarter. Velan Capital Investment Management LP increased its holdings in shares of Pyxis Oncology by 37.5% in the 3rd quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after acquiring an additional 15,000 shares during the last quarter. Finally, LPL Financial LLC raised its position in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after acquiring an additional 21,100 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PYXS has been the topic of several research analyst reports. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Royal Bank Of Canada cut their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Stifel Nicolaus reduced their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $7.00 price target while raising multiple EPS estimates — including FY2026 (from -$1.28 to -$0.95), FY2027 (to -$0.85), FY2028 (to -$0.34), FY2029 (to $0.27) and projecting FY2030 at $0.83 — and also lifted several quarterly forecasts. This analyst backing and upward revisions support a more bullish earnings trajectory for PYXS. HC Wainwright Reaffirms Buy for Pyxis Oncology
• Neutral Sentiment: Short‑interest data reported for March appears to show zero shares short (likely a reporting artifact); the published “days to cover” is 0.0 — this item is noisy and provides no clear directional signal.
• Negative Sentiment: Stifel Nicolaus lowered its price target from $9.00 to $8.00 (still a Buy) — a downward revision that reduces upside implied by that shop and may temper some investor enthusiasm. Stifel Lowers Expectations for Pyxis Oncology
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed multiple sales (most recently 13,896 shares at ~$1.03); insider selling can be perceived negatively by investors even if not uncommon for liquidity reasons. SEC filing: Director Form 4 Filing
• Negative Sentiment: Within HC Wainwright’s note there was a downward revision to Q2 2026 EPS (to -$0.36 from -$0.32), a modest near‑term hit to quarterly guidance amid the broader mixed revisions.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.